| __timestamp | Axsome Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 72471000 |
| Thursday, January 1, 2015 | 2419289 | 89204000 |
| Friday, January 1, 2016 | 6343648 | 106010000 |
| Sunday, January 1, 2017 | 7206691 | 137905000 |
| Monday, January 1, 2018 | 9351522 | 159888000 |
| Tuesday, January 1, 2019 | 13598030 | 158425000 |
| Wednesday, January 1, 2020 | 28896749 | 200677000 |
| Friday, January 1, 2021 | 66646205 | 304759000 |
| Saturday, January 1, 2022 | 159253661 | 377221000 |
| Sunday, January 1, 2023 | 323123000 | 336361000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing insights
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Axsome Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have taken different paths in optimizing these costs over the past decade.
From 2014 to 2023, Axsome Therapeutics saw a staggering increase in SG&A expenses, growing from a modest 1% of Supernus's 2014 expenses to nearly 96% by 2023. This reflects Axsome's aggressive expansion strategy. Meanwhile, Supernus Pharmaceuticals maintained a more consistent trajectory, with expenses peaking in 2022, indicating a stable yet growth-oriented approach.
Understanding these trends offers valuable insights into each company's strategic priorities. Axsome's rapid increase suggests a focus on scaling operations, while Supernus's steadier growth may indicate a balanced approach to cost management and market expansion.
AbbVie Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Sanofi and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Supernus Pharmaceuticals, Inc.
Grifols, S.A. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends